Frontiers in Medical Science Research, 2023, 5(8); doi: 10.25236/FMSR.2023.050814.
Wanjing Zhai1, Zhankui Wang1, Shilei Qin2, Pengfei Han3, Yunfeng Xu2,4
1Department of Graduate School, Graduate Student Department of Changzhi Medical College, Changzhi, Shanxi, 046000, China
2Department of Orthopaedics, Changzhi Yunfeng Hospital, Changzhi, Shanxi, 046000, China
3Department of Orthopedics, Heping Hospital of Changzhi Medical College, Changzhi, 046000, China
4Changzhi Spinal Disease Research Institute, Changzhi, Shanxi, 046000, China
Paget's disease of bone (PDB) is a non-inflammatory, metabolic skeletal disease. It is characterized by excessive bone resorption and irregular bone reconstruction. Its onset is often associated with both genetic and environmental factors. PDB is characterized by a very distinct geographical distribution, being more common in Western countries and rarer in Asia. The most significant susceptibility gene at the moment is SQSTM1. The imbalance between osteoclasts and osteoblasts is the main mechanism of its pathogenesis. The pelvis, spine, skull, femur, and tibia are most commonly involved, with less involvement in the upper limbs, clavicle, ribs, and scapula. It is less common before the age of 40, is predominantly male, and has a positive correlation between age and incidence. Pain and bone deformities are common manifestations of PDB. The diagnosis of PDB depends on imaging and biochemical markers. For the detection of PDBs, radionuclide bone scan is a more accurate test. Bisphosphonates are currently the leading therapeutic agent, and it has been shown that intravenous zoledronate provides remission in most patients and can prevent disease progression. In recent years, the number of related cases in China has gradually increased. The article summarizes relevant literature and analyzes relevant progress in order to provide help in the diagnosis and treatment of PDB.
Paget disease of bone; Bisphosphonate; Diagnosis; Treatment
Wanjing Zhai, Zhankui Wang, Shilei Qin, Pengfei Han, Yunfeng Xu. Latest Research Advances in Paget's Disease of Bone. Frontiers in Medical Science Research (2023) Vol. 5, Issue 8: 101-107. https://doi.org/10.25236/FMSR.2023.050814.
[1] Paget J. On a Form of Chronic Inflammation of Bones (Osteitis Deformans) [J]. Med Chir Trans, 1877, 60: 37-64.9.
[2] Makaram N S, Ralston S H. Genetic Determinants of Paget's Disease of Bone [J]. Curr Osteoporos Rep, 2021, 19(3): 327-37.
[3] Usategui-Martín R, Gestoso-Uzal N, Calero-Paniagua I, et al. A mutation in p62 protein (p. R321C), associated to Paget's disease of bone, causes a blockade of autophagy and an activation of NF-kB pathway [J]. Bone, 2020, 133: 115265.
[4] Gennari L, Rendina D, Merlotti D, et al. Update on the pathogenesis and genetics of Paget's disease of bone [J]. Front Cell Dev Biol, 2022, 10: 932065.
[5] Seton M, Choi H K, Hansen M F, et al. Analysis of environmental factors in familial versus sporadic Paget's disease of bone--the New England Registry for Paget's Disease of Bone [J]. J Bone Miner Res, 2003, 18(8): 1519-24.
[6] Morales-Piga A A, Rey-Rey J S, Corres-González J, et al. Frequency and characteristics of familial aggregation of Paget's disease of bone [J]. J Bone Miner Res, 1995, 10(4): 663-70.
[7] Galson D L, Roodman G D. Pathobiology of Paget's Disease of Bone [J]. J Bone Metab, 2014, 21(2): 85-98.
[8] Matthews B G, Afzal M A, Minor P D, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease [J]. J Clin Endocrinol Metab, 2008, 93(4): 1398-401.
[9] Teramachi J, Nagata Y, Mohammad K, et al. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease [J]. J Clin Invest, 2016, 126(3): 1012-22.
[10] Wang F M, Sarmasik A, Hiruma Y, et al. Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling [J]. Bone, 2013, 53(1): 269-76.
[11] Rogers J, Jeffrey D R, Watt I. Paget's disease in an archeological population [J]. J Bone Miner Res, 2002, 17(6): 1127-34.
[12] Mays S. Archaeological skeletons support a northwest European origin for Paget's disease of bone [J]. J Bone Miner Res, 2010, 25(8): 1839-41.
[13] Gendron E, Bouchard F, Singbo N, et al. Decline in clinical severity of Paget's disease of bone: Comparison between a contemporary cohort and a historical cohort [J]. Bone, 2023, 170: 116721.
[14] Cook M J, Pye S R, Lunt M, et al. Incidence of Paget's disease of bone in the UK: evidence of a continuing decline [J]. Rheumatology (Oxford), 2021, 60(12): 5668-76.
[15] Varenna M, Zucchi F, Crotti C, et al. Decreasing severity of Paget's disease of bone in northern Italy over the last two decades: results of a monocentric study on 391 patients [J]. Osteoporos Int, 2021, 32(9): 1795-801.
[16] Nebot Valenzuela E, Pietschmann P. Epidemiology and pathology of Paget's disease of bone - a review [J]. Wien Med Wochenschr, 2017, 167(1-2): 2-8.
[17] Rabjohns E M, Hurst K, Ghosh A, et al. Paget's Disease of Bone: Osteoimmunology and Osteoclast Pathology [J]. Curr Allergy Asthma Rep, 2021, 21(4): 23.
[18] Fuentes-Calvo I, Usategui-Martín R, Calero-Paniagua I, et al. Influence Of Angiogenic Mediators And Bone Remodelling In Paget´s Disease Of Bone [J]. Int J Med Sci, 2018, 15(11): 1210-6.
[19] Amaya N, Itoiz M E, Paparella M L. Paget's disease of the jaws: Histopathological features of a series of 31 cases [J]. Acta Odontol Latinoam, 2021, 34(3): 257-62.
[20] Tao X, Liu L, Yang X, et al. Clinical Characteristics and Pathogenic Gene Identification in Chinese Patients With Paget's Disease of Bone [J]. Front Endocrinol (Lausanne), 2022, 13: 850462.
[21] Tan A, Ralston S H. Clinical presentation of Paget's disease: evaluation of a contemporary cohort and systematic review [J]. Calcif Tissue Int, 2014, 95(5): 385-92.
[22] Shaker J L. Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management [J]. Ther Adv Musculoskelet Dis, 2009, 1(2): 107-25.
[23] Sabharwal R, Gupta S, Sepolia S, et al. An Insight in to Paget's Disease of Bone [J]. Niger J Surg, 2014, 20(1): 9-15.
[24] Maldague B, Malghem J. Dynamic radiologic patterns of Paget's disease of bone [J]. Clin Orthop Relat Res, 1987, (217): 126-51.
[25] Horino T, Ichii O, Terada Y. Cotton Wool Sign in Paget Disease of Bone [J]. Intern Med, 2019, 58(12): 1809-10.
[26] Zimmermann E A, Köhne T, BALE H A, et al. Modifications to nano- and microstructural quality and the effects on mechanical integrity in Paget's disease of bone [J]. J Bone Miner Res, 2015, 30(2): 264-73.
[27] Ralston S H, Corral-Gudino L, Cooper C, et al. Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline [J]. J Bone Miner Res, 2019, 34(4): 579-604.
[28] Winn N, Lalam R, Cassar-Pullicino V. Imaging of Paget's disease of bone [J]. Wien Med Wochenschr, 2017, 167(1-2): 9-17.
[29] Al Nofal A A, Altayar O, Benkhadra K, et al. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis [J]. Osteoporos Int, 2015, 26(7): 1875-91.
[30] Gillett M J, Vasikaran S D, Inderjeeth C A. The Role of PINP in Diagnosis and Management of Metabolic Bone Disease [J]. Clin Biochem Rev, 2021, 42(1): 3-10.
[31] Reid I R, Davidson J S, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone [J]. Bone, 2004, 35(1): 224-30.
[32] Guay-Bélanger S, Simonyan D, Bureau A, et al. Development of a molecular test of Paget's disease of bone [J]. Bone, 2016, 84: 213-21.
[33] Singer F R, Bone H G, 3rd, Hosking D J, et al. Paget's disease of bone: an endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab, 2014, 99(12): 4408-22.
[34] Meyers M H, Singer F R. Osteotomy for tibia vara in Paget's disease under cover of calcitonin [J]. J Bone Joint Surg Am, 1978, 60(6): 810-4.
[35] Singer F R, Fredericks R S, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance [J]. Arthritis Rheum, 1980, 23(10): 1148-54.
[36] Corral-Gudino L, Tan A J, Del Pino-Montes J, et al. Bisphosphonates for Paget's disease of bone in adults [J]. Cochrane Database Syst Rev, 2017, 12(12): Cd004956.
[37] Licata A A. Discovery, clinical development, and therapeutic uses of bisphosphonates [J]. Ann Pharmacother, 2005, 39(4): 668-77.
[38] Ralston S H. Clinical practice. Paget's disease of bone [J]. N Engl J Med, 2013, 368(7): 644-50.
[39] Reid I R, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease [J]. N Engl J Med, 2005, 353(9): 898-908.
[40] Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion [J]. J Bone Miner Res, 2010, 25(3): 447-54.
[41] Reid I R, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years [J]. J Bone Miner Res, 2011, 26(9): 2261-70.
[42] Makaram N, Woods L, Beattie N, et al. Long-term outcomes following total hip and total knee arthroplasty in patients with Paget's disease of bone (PDB) - A national study [J]. Surgeon, 2020, 18(6): 335-43.
[43] Popat R, Tsitskaris K, Millington S, et al. Total knee arthroplasty in patients with Paget's disease of bone: A systematic review [J]. World J Orthop, 2018, 9(10): 229-34.
[44] Hanna S A, Dawson-Bowling S, Millington S, et al. Total hip arthroplasty in patients with Paget's disease of bone: A systematic review [J]. World J Orthop, 2017, 8(4): 357-63.
[45] Wegrzyn J, Pibarot V, Chapurlat R, et al. Cementless total hip arthroplasty in Paget's disease of bone: a retrospective review [J]. Int Orthop, 2010, 34(8): 1103-9.
[46] Fukui K, Kaneuji A, Yonezawa K, et al. Catastrophic failure of cup revision hip arthroplasty due to undiagnosed Paget disease of bone: A case report [J]. Int J Surg Case Rep, 2020, 76: 5-10.
[47] Merlotti D, Rendina D, Cavati G, et al. Drug treatment strategies for paget's disease: relieving pain and preventing progression [J]. Expert Opin Pharmacother, 2023, 24(6): 715-27.